drugset / Trial / NCT00500344

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

NCT00500344

NaSingle-groupOpen-labelTreatment

Summary

CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD

Timeline

Start
2007-07
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal